LGVN Q1 2025 Earnings — Longeveron Inc. Revenue & Financial Results | Market Cap Arena

LGVNLongeveron Inc.

$20M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$381,000-30.5% YoY

Gross Profit

$275,00072.2% margin

Operating Income

-$5M-1359.8% margin

Net Income

-$5M-1315.2% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

-36.8%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$340,000

Balance Sheet

Total Assets

$21M

Total Liabilities

$4M

Stockholders' Equity

$17M

Cash & Equivalents

$14M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$381,000	$548,000	-30.5%
Gross Profit	$275,000	$329,000	-16.4%
Operating Income	-$5M	-$4M	-26.7%
Net Income	-$5M	-$4M	-23.5%